NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
If implemented across the world, it has the capability to save over 100,000 lives annually
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
Subscribe To Our Newsletter & Stay Updated
